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A b s t r a c t 
Objectives: To determine the Etest-based epidemiological cut-off values (ECVs) for antifungal agents 
against the most frequent yeast and Aspergillus fumigatus species isolated in 12 French hospitals. Methods: 
For each antifungal agent, the Etest MICs in yeast and A. fumigatus isolates from 12 French laboratories 
were retrospectively collected from 2004 to 2018. The ECVs were then calculated using the iterative 
statistical method with a 97.5% cut-off. 
Results: Forty-eight Etest ECVs were determined for amphotericin B, caspofungin, micafungin, anidula- fungin, 
ﬂuconazole, voriconazole, posaconazole and itraconazole, after pooling and analysing the MICs of 9654 Candida 
albicans, 2939 Candida glabrata SC, 1458 Candida parapsilosis SC, 1148 Candida tropicalis, 575 Candida 
krusei, 518 Candida kefyr, 241 Candida lusitaniae, 131 Candida guilliermondii and 1526 Aspergillus 
fumigatus species complex isolates. These ECVs were 100% concordant (identical or within one two-fold 
dilution) with the previously reported Etest-based ECVs (when available), and they were concordant in 
76.1% of cases with the Clinical and Laboratory Standards Institute ECVs and in 81.6% of cases with the 
European Committee on Antimicrobial Susceptibility Testing ECVs. 
Conclusions: On the basis of these and other previous results, we recommend the determination of 
method-dependent ECVs. Etest ECVs should not be used instead of breakpoints, but may be useful to 
identify non-wild-type isolates with potential resistance to antifungal agents, and to indicate that an 
isolate may not respond as expected to the standard treatment. 
* Corresponding  author.  M.  Sasso,  Service  de  Parasitologie-Mycologie,  CHU Nîmes, Universite' Montpellier, Nîmes, France.
E-mail address: milene.sasso@chu-nimes.fr (M. Sasso). 
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Introduction 
The prevalence of invasive infections due to fungal pathogens continues to increase in immunocompromised 
individuals. In France, candidiasis represents the primary cause (49%) of invasive fungal diseases, of which 
56% are due to Candida albicans, 18.6% to Candida glabrata, 11.5% to Candida parapsilosis, and 9.3% to Candida 
tropicalis. Aspergillosis is in third position (16% of all invasive fungal diseases) [1]. To manage these invasive 
fungal diseases, three classes of antifungal agents (polyenes, echinocandins and azoles) are recommended as 
initial or salvage therapy [2,3]. The Clinical and Laboratory Standards Institute (CLSI) and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) have established standard procedures for testing the 
susceptibility of fungi to anti- fungal agents, and have proposed species-speciﬁc breakpoints for interpreting 
the MICs of some antifungal agents against the most prevalent Candida spp. [4e6]. Species-speciﬁc 
breakpoints predict the likelihood of clinical response to antimicrobial therapy. How- ever, there are many 
pathogeneantifungal agent combinations for which clinical breakpoints are not available, because of insufﬁcient 
data to correlate the clinical outcomes with the in vitro results. When only MIC data are available, 
epidemiological cut-off values (ECVs or ECOFF) should be considered. ECVs are deﬁned as the highest 
susceptibility end point of the MIC distribution for the wild- type (WT) population. A MIC value higher than the 
ECV suggests that the isolate may have developed resistance to that agent, so an alternative compound should 
be considered [7,8]. ECVs are dependent on the in vitro sensitivity testing method used to generate the MIC 
values. Although ECVs for several organismeantifungal agent combinations have been published [9e19], few 
data are available on ECVs based on the MIC distribu- tions  obtained  with  commercial  methods.  As  the  
gradient  agar 
diffusion-based Etest assay (bioMe'rieux, Marcy l’Etoile, France) is 
often used in the clinical routine [10,11,13], we collected retro- spectively the MICs for yeast and 
Aspergillus fumigatus species complex (SC) isolates obtained with the Etest method at 12 French mycological 
laboratories to determine the ECVs of the main agents used in the clinical practice, in order to harmonize the 
interpreta- tion of the Etest MIC results. 
Material and methods 
MIC data collection 
The MICs for different antifungal agents tested on cultured pa- tient isolates with the Etest from 2004 to 
2018 were collected retrospectively from the laboratories of 12 French university hos- pitals (CHU de Nîmes, 
CHU de Rennes, CHU de Toulouse, CHU de Bordeaux, Hospices Civils de Lyon, CHU de Rouen, CHU de 
Mont- pellier, CHU de Limoges, APHP Ho^pital universitaire Pitie'-Sal- pe'trie're, APHP Ho^pital Bichat-
Claude Bernard, APHP Ho^pital Europe'en Georges Pompidou and APHP Ho^ pital Henri Mondor). 
Species identiﬁcation and antifungal susceptibility testing 
The tested isolates were from routine specimen cultures (blood cultures, sterile sites and other sites, such as 
bronchoalveolar lavage, sputum) that required antifungal susceptibility testing for therapeutic management. Fungi  
were  identiﬁed  using  different  methods:  phenotypic features in chromogenic medium, microscopic morphology, 
VITEK®2 YST system (bioMe'rieux), API® ID32C (bioMe'rieux) or mass spectrometry (Bruker Microﬂex LT™ 
system, BrukerDaltonik, Bremen, Germany, or VITEK® MS, bioMe'rieux). The Etest-based MIC values for the 
following species could be collected: C. albicans, C. glabrata SC, C. parapsilosis SC, C. tropicalis, Candida krusei, 
Candida kefyr, Candida lusitaniae, Candida guillier- mondii and A. fumigatus SC. Each laboratory determined the 
isolate susceptibility to different antifungal drugs (amphotericin B, anidulafungin, 
caspofungin, micafungin, 5-ﬂuorocytosine,  ﬂuconazole,  itracona- zole, posaconazole and voriconazole) using the 
Etest  gradient diffusion  method,  according  to  the  manufacturer's  instructions [20]. Etest MICs were determined 
by visual observation at 48 h of growth for yeasts, and between 16 and 72 h, depending on their growth, for A. 
fumigatus SC. During the study period, all contrib- uting laboratories tested the quality control reference strains. 
The MICs obtained for these strains were all within the expected reference ranges. All Etest MIC readings were 
performed by quali- ﬁed operators. In 2018, in parallel with data collection, to test the inter-operator variability 
among centres,  each  reader  determined the MICs based on visual inspection of 16 photographs of Etest assays. 
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No signiﬁcant difference between the determined MICs was observed. 
ECV  determination 
To ensure that robust and comparable data were included for the ECV estimation, the following basic 
requirements and criteria needed to be fulﬁlled [9]. (i) MICs were converted into the standard two-fold dilution 
scale based on dilution factor values that are powers of 2 (at the upper dilution). All data were collected in the 
form of number of isolates with different MIC values on the power of 2 scale. The MIC mode was the MIC 
value with the highest number of representative isolates. (ii) If the MIC mode of a distri- bution was at the 
lowest tested concentration, or if the distribution appeared truncated before or after the MIC mode, that 
distribution was excluded. (iii) Distributions with aberrant MIC modes were excluded: for example, when the 
MIC mode of the distribution was two-fold or more than two-fold dilutions above or below the most frequent 
WT mode. (iv) MIC data were not pooled if there was no obvious common mode among the range of 
distributions (for example bimodal distributions). (v) If one of the participating lab- oratories contributed >50% 
of the values to the pooled data, the MIC data were normalized to reduce this bias in the estimate. (vi) MIC data 
were pooled only if generated by at least three independent laboratories. (vii) For each specieseantifungal 
agent combination, a minimum of 100 MIC values were required after data pooling. 
The ECVs from pooled data were estimated using the iterative statistical method (ISM) described by 
Turnidge et al. [7] and implemented in a MICROSOFT EXCEL® ECOFFINDER workbook (https:// 
www.clsi.org/meetings/microbiology/ecofﬁnder/). This method selects the log normal distribution for 
subsequent modelling. From the real MIC distribution (power of 2 scale), the ISM attempts to ﬁt iteratively the 
observed WT counts in a log normal distribution and creates a range of possible ECVs. This ﬁtted log-normal 
distribution is a probability distribution of the WT population. Each resulting 
Etest ECV corresponded to the MIC that captured 97.5% of the 
modeled WT population, and represented the probability for an isolate to be a WT isolate if its MIC was 
lower or equal to the ECV value. 
Ethics 
This study included only data from fungal isolates. The opinion of an Institutional Review Board was not 
required because human participants were not involved. 
Results 
Analysis of the data allowed determination of 48 ECVs for nine yeast and one mould species (total number 
of included isolates: 9654 C. albicans, 2939 C. glabrata SC, 1458 C. parapsilosis SC, 1148 C.  tropicalis,  575  C. 
krusei,  518  C.  kefyr,  241  C.  lusitaniae,  131 C.  guilliermondii  and  1526  A.  fumigatus  SC).  Depending  on  the 
species and antifungal agent, MIC data from 3 to 12 laboratories were pooled. The MIC distributions for 
each speciesemolecule combination are presented in Table 1. 
The Etest-based ECVs of amphotericin B and echinocandins for Candida spp. are presented in Table 2. ECVs 
were determined for the ﬁve  main  species  (C.  albicans,  C.  glabrata,  C.  parapsilosis  SC, 
C. tropicalis and C. krusei) using MIC data on 117 to 6062 isolates, according to the specieseantifungal agent 
combination. Enough data (>100 isolates) were collected to determine new ECVs for less prevalent species, such 
as C. kefyr, C. guilliermondii and C. lusitaniae. 
The MICs determined for Candida spp. and azoles (Table 3) allowed the calculation of 15 ECVs. It was not 
possible to estimate the Etest-based ECVs for C. glabrata and azoles because of the aberrant MIC distribution 
observed with the Etest method (double peak). Moreover, the ECV for the C. kruseieﬂuconazole combination was 
not determined because of its innate resistance to this drug. 
To calculate the ECVs for A. fumigatus SC (Table 4), data on 361 to 1027  isolates  were  used,  depending  on  the 
specieseantifungal agent combination. Two new ECVs were determined for echino- candins. The ECVs for A. 
fumigatus SC and amphotericin B  and azoles  were  similar  to  those  previously  reported. 
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Overall, the ECV results were identical to (17/32 ECVs) or within one two-fold dilution of (15/32 ECVs) the 
previously reported Etest- based ECVs (Tables 2e4). They were comparable to the CLSI ECVs in 76.1% (similar or 
within one two-fold dilution: 35/46 ECVs) and absolutely identical in 39.1% of cases (18/46 ECVs). They 
were comparable to the EUCAST ECVs in 81.2% of cases (similar or within one two-fold dilution: 26/32 ECVs) 
and strictly identical in 28% (9/ 32 ECVs). 
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M. Sals'e et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 
0.001 0.002 0.004 0.008 0.016 0.032 0.064 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Candida albicans Amphotericin  B 6062 11 6 8 0 8 18 92 297 1079 2803 1569 159 19 1 0 1 0 2 0 0 0 
Caspofungin 5783 12 0 5 14 125 615 1572 1891 1220 294 34 5 1 2 2 1 1 1 0 0 0 
Micafungin 3752 11 0 6 59 855 1909 822 62 13 9 9 6 1 0 0 0 1 0 0 0 0 
Anidulafungin 1593 5 3 560 674 289 38 9 7 3 6 0 0 1 2 0 1 0 0 0 0 0 
Fluconazole 9654 12 0 0 0 0 5 59 519 2501 3880 1908 488 147 48 21 20 12 7 1 10 28 
Voriconazole 6020 12 5 327 1551 2161 1272 434 141 57 36 13 6 4 0 0 0 8 5 0 0 0 
Posaconazole 1005 6 0 5 13 151 428 288 72 25 8 7 6 1 1 0 0 0 0 0 0 0 
Candida glabrata SC Amphotericin  B 2272 11 0 0 0 0 4 11 31 93 288 995 712 113 16 2 4 0 3 0 0 0 
Caspofungin 2292 11 0 0 3 0 16 44 312 1121 688 66 19 4 3 4 1 1 6 0 0 4 
Micafungin 1494 11 0 0 2 98 988 359 7 5 6 10 3 9 3 3 0 1 0 0 0 0 
Anidulafungin 513 5 0 0 8 67 353 61 8 4 4 0 3 1 2 1 1 0 0 0 0 0 
Fluconazole 2939 11 0 0 0 0 1 0 2 5 9 20 28 97 204 375 722 557 213 91 100 515 
Voriconazole 2304 11 0 4 8 13 16 57 120 326 409 423 266 145 117 95 72 61 172 0 0 0 
Posaconazole 455 7 0 0 0 1 3 2 5 14 24 49 56 63 46 35 14 58 85 0 0 0 
Candida parapsilosis SC Amphotericin  B 981 10 0 1 0 1 5 17 28 53 155 390 271 48 9 1 0 0 2 0 0 0 
Caspofungin 1091 10 0 0 0 1 0 2 8 28 203 395 304 119 22 4 1 0 4 0 0 0 
Micafungin 839 11 0 0 2 1 2 1 0 4 24 102 388 234 73 5 3 0 0 0 0 0 
Anidulafungin 241 3 0 0 0 0 0 0 1 1 4 16 60 80 43 12 3 4 17 0 0 0 
Fluconazole 1458 12 0 0 0 0 4 8 22 111 337 445 288 124 40 24 19 11 5 0 3 17 
Voriconazole 1150 12 0 31 111 264 285 236 118 47 18 11 8 8 9 1 0 0 3 0 0 0 
Candida tropicalis Amphotericin  B 787 10 0 0 0 1 1 3 29 49 146 295 222 36 5 0 0 0 0 0 0 0 
Caspofungin 787 10 0 1 1 2 18 59 208 300 163 23 6 3 2 0 0 0 1 0 0 0 
Micafungin 504 11 0 0 0 1 61 338 96 4 1 0 0 3 0 0 0 0 0 0 0 0 
Anidulafungin 213 5 0 2 7 50 123 24 4 2 0 0 0 1 0 0 0 0 0 0 0 0 
Fluconazole 1148 12 0 0 0 0 1 1 3 15 82 301 409 229 52 22 9 5 4 1 1 13 
Voriconazole 886 12 0 2 5 16 106 211 308 165 31 16 8 3 1 2 2 3 7 0 0 0 
Posaconazole 152 4 0 1 0 7 32 45 34 21 9 2 1 0 0 0 0 0 0 0 0 0 
Candida krusei Amphotericin  B 534 9 0 0 0 1 1 4 6 18 40 144 207 96 15 1 0 1 0 0 0 0 
Caspofungin 565 10 0 0 0 0 0 1 3 16 139 303 81 18 4 0 0 0 0 0 0 0 
Micafungin 259 5 0 1 0 1 1 3 7 106 137 2 1 0 0 0 0 0 0 0 0 0 
Anidulafungin 117 3 0 2 0 0 27 43 37 5 3 0 0 0 0 0 0 0 0 0 0 0 
Fluconazole 414 11 0 0 0 0 0 0 0 0 0 3 1 1 0 1 21 65 81 23 47 171 
Voriconazole 575 10 0 0 0 0 2 5 20 79 183 212 49 14 7 2 1 0 1 0 0 0 
Candida kefyr Amphotericin  B 353 9 0 0 1 0 2 8 26 45 90 161 16 4 0 0 0 0 0 0 0 0 
Caspofungin 418 8 0 0 0 0 8 49 113 212 33 3 0 0 0 0 0 0 0 0 0 0 
Micafungin 236 7 0 0 0 0 2 30 126 73 5 0 0 0 0 0 0 0 0 0 0 0 
Fluconazole 518 11 0 0 0 0 1 4 39 141 197 114 15 4 0 1 0 0 0 0 2 0 
Voriconazole 357 9 0 20 63 141 95 29 4 2 2 1 0 0 0 0 0 0 0 0 0 0 
Candida lusitaniae Amphotericin  B 170 9 0 0 0 1 0 7 7 28 70 47 5 5 0 0 0 0 0 0 0 0 
Caspofungin 149 7 0 0 0 0 3 5 14 39 59 24 4 1 0 0 0 0 0 0 0 0 
Fluconazole 241 10 0 0 0 0 2 9 21 44 83 54 13 2 2 3 2 3 1 0 0 2 
Voriconazole 168 8 1 20 39 67 23 3 3 5 3 3 1 0 0 0 0 0 0 0 0 0 
Candida guilliermondii Amphotericin  B 131 6 0 0 0 1 12 14 28 25 34 15 1 1 0 0 0 0 0 0 0 0 
Caspofungin 120 5 0 0 0 0 0 0 2 10 34 41 23 4 2 1 0 0 3 0 0 0 
Fluconazole 111 5 0 0 0 0 0 0 0 0 1 10 26 31 9 10 4 5 3 2 0 10 
Voriconazole 115 5 0 0 0 2 25 26 22 6 5 7 6 3 0 1 0 3 3 0 0 6 
Aspergillus fumigatus SC Amphotericin  B 1027 9 0 1 0 0 1 6 9 63 225 505 178 27 7 3 1 1 0 0 0 0 
Caspofungin 806 5 0 2 12 65 193 251 191 75 16 1 0 0 0 0 0 0 0 0 0 0 
Micafungin 361 5 0 14 90 165 75 14 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
Voriconazole 1526 7 0 1 1 1 1 13 50 662 622 109 29 18 10 4 2 0 3 0 0 0 
Posaconazole 961 8 0 2 2 4 20 68 367 391 75 17 3 6 1 0 1 0 4 0 0 0 
Itraconazole 989 7 0 0 0 0 1 4 10 39 190 474 199 35 4 8 6 4 15 0 0 0 
3 
Table 1 
Pooled MIC distributions of Candida species and Aspergillus fumigatus SC 
Species Antifungal drug   Tested 
isolates (n) 
From number 
of laboratories 
No. of isolates with MIC (mg/L) ofa: 
a  The MIC mode (most frequent value) for each distribution is in bold type. Ac
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5 
Candida albicans 11/12 6062/6249 0.25 1 1 2 1 d 1 
Candida glabrata SC 11/12 2272/2446 0.5 2 2 2 1 d 1 
Candida parapsilosis SC 10/11 981/1137 0.5 2 2 2 1 d 1 
Candida tropicalis 10/12 787/866 0.5 2 2 2 1 d 1 
Candida krusei 9/11 534/603 1 4 4 2 1 d 1 
Candida kefyr 9/11 353/380 0.5 2 d d d d d 
Candida lusitaniae 9/11 170/189 0.25 1 d 2 d d d 
Candida guilliermondii 6/11 131/164 0.25 1 d 2 d d d 
 Candida albicans 5/5 1593/1593 0.004 0.008 0.016 0.12 0.03 0.25/1 0.03/0.03 
Candida glabrata SC 5/5 513/513 0.016 0.03 0.03 0.12 0.06 0.12/0.5 0.06/0.06 
Candida parapsilosis SC 3/4 241/259 2 8* 8* 8 4 2/8 0.002/4 
Candida tropicalis 5/5 213/213 0.016 0.03 0.03 0.12 0.06 0.25/1 0.06/0.06 
Candida krusei 3/3 117/117 0.03 0.12* 0.06 0.25 0.06 0.25/1 0.06/0.06 
 
Discussion 
The Etest method is widely used in the clinic, and MIC inter- pretation is based on the CLSI breakpoints 
that are, however, available only for some specieseantifungal drug combinations [21]. In their absence,  the 
method-dependent  ECVs  allow  identiﬁcation of non-WT isolates that might be resistant to an antifungal agent. 
ECVs for some specieseantifungal agent combinations have been established using both reference methodsdCLSI 
[9,12,15e19] and EUCAST [9,10,14,22,23]dand some commercial methods, such as Sensititre YeastOne [24] and 
Etest [10,11,13]. In this study, we collected the MIC  values  (obtained  with  the  Etest) for  more than 18 000 
Candida spp. and A. fumigatus SC isolates and calculated the 
Etest-based ECVs (n ¼ 48) using the ISM [7] at the 97.5% cut-off 
value to exclude isolates with extreme MICs. This analysis included the ﬁve Candida species responsible for 
more than 90% of invasive candidiasis and all the classes of antifungal agents rec- ommended in the 
guidelines [2,3] (except for C. glabrata and azoles), as well as less prevalent Candida species (C. lusitaniae, 
C. guilliermondii, C. kefyr), and A. fumigatus SC. Currently, only three other  studies  used  the  ISM  and  Etest  data 
to  calculate  the  ECVs (n ¼ 50) of some antifungal agents for six Candida spp. and ﬁve Aspergillus spp. 
[10,11,13]). 
Table 2 
Etest epidemiological cut-off values of amphotericin B and echinocandins in Candida spp. 
Contributing Used isolates/ MIC mode Etest ECV Etest ECVs CLSI EUCAST CLSI BPs EUCAST 
laboratories/total ( n) total (n) (mg/L) (this study)a (Espinel-Ingroff)b ECVsc ECVsd S�/R  
e
� BPs S�/R >f
Amphotericin  B 
Anidulafungin 
Micafungin 
Candida albicans 11/11 3752/3752 0.016 0.03 0.03 0.03 0.016 0.25/1 0.016/0.016 
Candida glabrata SC 11/11 1494/1494 0.016 0.03 0.03 0.03 0.03 0.06/0.25 0.03/0.03 
Candida parapsilosis SC 11/11 839/839 1 4 2 4 2 2/8 0.002/2 
Candida tropicalis 11/11 504/504 0.03 0.06 0.12 0.06 0.06 0.25/1 d 
Candida krusei 5/11 259/402 0.25 0.5 0.25 0.25 0.25 0.25/1 d 
Candida kefyr 7/11 236/254 0.06 0.25 d 0.12 d d d 
Caspofungin 
Candida albicans 12/12 5783/5783 0.06 0.25 0.5 0.12 d 0.25/1 d 
Candida glabrata SC 11/12 2292/2303 0.12 0.5 1 0.12 d 0.12/0.5 d 
Candida parapsilosis SC 10/12 1091/1109 0.5 2 4 1 d 2/8 d 
Candida tropicalis 10/12 787/798 0.12 0.5 1 0.12 d 0.25/1 d 
Candida krusei 10/12 565/568 0.5 1 1 0.25 d 0.25/1 d 
Candida kefyr 8/10 418/446 0.12 0.25 d 0.03 d d d 
Candida lusitaniae 7/10 149/175 0.25 1 d 1 d d d 
Candida guilliermondii 5/9 120/152 0.5 2 d 2 d 2/8 d 
Abbreviations: BP, breakpoint; ECV, epidemiological cut-off value; MIC mode, most frequent MIC in the distribution; R, resistant; S, susceptible; SC, species complex. 
*ECV obtained after data normalization (>50% of all data were from one laboratory).
a ECVs calculated for the modelled population (�97.5%). 
b ECVs determined by Espinel-Ingroff et al. with the Etest method (�97.5%) [13]. 
c ECVs determined using the CLSI method in previous studies [9,15e17,19]. 
d ECVs determined using the EUCAST method [9,14,23]. 
e CLSI breakpoints [15,21]. 
f EUCAST breakpoints [6]. 
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Candida albicans 12/12 9654/9654 0.25 1 d 1 0.5 1 2/8 2/4 
Candida glabrata SC 0/11 0/2939 d d 64 32 8 32 SDD�32/R � 64 0.002/32 
Candida parapsilosis SC 12/12 1458/1458 0.5 2 4 2 1 2 2/8 2/4 
Candida tropicalis 12/12 1148/1148 1 4 4 2 1 2 2/8 2/4 
Candida krusei 11/11 414/414 >256 d d 128 32 128 d d 
Candida kefyr 11/12 518/527 0.25 1 d d 1 d d d 
Candida lusitaniae 10/10 241/241 0.25 1 d d 1 16 d d 
Candida guilliermondii 5/10 111/186 2 4 d d 8 16 d d 
 
� 
Table 3 
Etest epidemiological cut-off values for azoles and Candida spp. 
Contributing 
laboratories/ 
total (n) 
Used isolates/ 
total (n) 
MIC mode 
(mg/L) 
EtestECVs 
(this  study)a 
EtestECVs 
(Espinel- 
Ingroff)b1 
Etest ECVs 
(EUCAST 
determination)b2
CLSI 
ECVsc
EUCAST 
ECVsd
CLSI BPs 
S�/R  e
EUCAST BPs 
S�/R>f
Fluconazole 
Voriconazole 
Candida albicans 12/12 6020/6020 0.008 0.03 0.03 0.12 0.03 0.12 0.12/1 0.06/0.25 
Candida glabrata SC 0/11 0/2304 d d 2 1 0.25 1 d d 
Candida parapsilosis SC 12/12 1150/1150 0.016 0.12 0.25 0.12 0.03 0.12 0.12/1 0.12/0.25 
Candida tropicalis 12/12 886/886 0.06 0.25 0.5 0.12 0.06 0.12 0.12/1 0.12/0.25 
Candida krusei 10/12 575/673 0.5 1 2 1 0.5 1 0.5/2 d 
Candida kefyr 9/11 357/374 0.008 0.03 d d 0.016 d d d 
Candida lusitaniae 8/11 168/189 0.008 0.03 d 0.06 0.03 0.06 d d 
Candida guilliermondii 5/10 115/163 0.03 0.12 d 0.25 0.12 0.25 d d 
Posaconazole 
Candida albicans 6/7 1005/1014 0.016 0.06 0.12 d 0.06 0.06 d 0.06/0.06 
Candida glabrata SC 0/7 0/455 d d d d 2 1 d d 
Candida tropicalis 4/6 152/159 0.03 0.25* 0.12 d 0.12 0.06 d 0.06/0.06 
Abbreviations: BP, breakpoint; ECV, epidemiological cut-off value; MIC mode, most frequent MIC in the distribution; R, resistant; S, susceptible; SC, species complex. 
*ECV obtained after data normalization (>50% of all data were from one laboratory).
a  ECVs calculated for the modelled population (�97.5%). 
b1  ECVs determined by Espinel-Ingroff et al. with the Etest method (�97.5%) [11]. 
b2  Etest-based ECVs determined by the EUCAST organization [23]. 
c ECVs determined with the CLSI method in previous studies [9,11,12,17]. 
d ECVs determined with the EUCAST method [5,9,14,23]. 
e CLSI breakpoints [15,21]. 
f EUCAST breakpoints [6]. 
For the Candida spp.eamphotericin B combinations, we deter- mined eight ECVs, of which three were new 
and ﬁve displayed the same values as those reported by Espinel-Ingroff et al. [13]. 
For the Candida spp.-echinocandin combinations, our Etest ECVs were identical (6/15 ECVs) or within one 
two-fold dilution (9/15 ECVs) compared with the previously published values. These non- signiﬁcant 
discrepancies could be explained by the higher number of isolates analysed in our study (e.g. 5783 C. albicans 
isolates for caspofungin and 504 C. tropicalis isolates for micafungin versus 2537 and 140 isolates, 
respectively, in [13]). Espinel-lngroff et al. showed that the Etest ECVs for anidulafungin identiﬁed 92% of FKS 
mutants as non-WT isolates (versus 75% and 84% with the ECVs for caspofungin and micafungin, respectively) 
[13]. The authors concluded that the Etest ECVs for anidulafungin could represent a surrogate marker for 
echinocandin resistance screening in Candida spp., as also suggested by Pfaller et al. with the CLSI method [25]. 
In our study, the ECVs for caspofungin were most often lower (one two-fold dilution) than those  reported by 
Espinel-Ingroff et al., which raised the question of selecting a robust surrogate marker for echinocandin 
resistance screening. To determine the most useful echinocandin ECV to identify non-WT isolates, it might be 
neces- sary to test isolates with characterized mutations. 
For the Candida spp.eazole combinations, among the Etest- based ECVs previously published [11], two 
were similar and six were within one two-fold dilution. Other Etest ECVs are available for azoles in the 
EUCAST website (https://mic.eucast.org/Eucast2/) [23], but they were determined using a small number of 
strains, sometimes <100 observations for some specieseantifungal agent combinations. There was no 
signiﬁcant difference (i.e. more than one two-fold dilution) between our ECVs and the EUCAST ECVs, but for 
the C. albicansevoriconazole combination (ECV ¼ 0.03 mg/L in our study and 0.12 mg/L by EUCAST). However, 
our ECV is identical to the one reported by Espinel-Ingroff et al., suggesting that this is a more  robust  value.  We 
could  not  determine  the  Etest  ECVs  for 
C. glabrata SC and azoles because of the aberrant MIC distribution (double peak). Indeed, there was a 
signiﬁcant number of strains with high MICs (>256 mg/L) due to the appearance of ‘macro-col- onies’ in the 
inhibition ellipse when MICs were read at 48 h. Some authors have found lower rates of agreement for C. 
glabrata and azoles when comparing the Etest and the CLSI method (higher MICs with the Etest) [26,27]. The 
incubation time seems to inﬂuence the results. Indeed, a better agreement between these methods is observed 
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 7 at 24 h of growth and reading. In their latest study to determine the ECVs for C. glabrata SC and azoles, 
Espinel-Ingroff et al. read the Etest MICs between 24 h and 48 h, depending on the growth [11]. This may 
explain why they did not observe double peaks and could, therefore, estimate the ECVs. 
In our study, we could determine the Etest ECVs for antifungal agents used as ﬁrst-line and also salvage 
therapy of the most prevalent species of invasive aspergillosis (A. fumigatus SC). In contrast to our study, 
Espinel-Ingroff et al. observed a signiﬁcant heterogeneity in the minimum effective concentration mode 
for Aspergillus spp. and caspofungin, and could not determine the Etest ECVs [13]. The new identiﬁcation 
methods (especially matrix- assisted laser desorption/ionization time-of-ﬂight) that can also identify 
cryptic species will allow determination of the ECVs for species within a complex. This is important 
because the suscepti- bility to an antifungal drug is not the same for all species within a complexdfor 
example, Aspergillus lentulus shows higher MICs to amphotericin B) [28]. 
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Table 4 
Etest epidemiological cut-off values for the Aspergillus fumigatus species complex 
Contributing 
laboratories/total (n) 
Used isolates/ 
total (n) 
MIC mode 
(mg/L) 
EtestECVs 
(this  study)a 
Etest ECVs 
(Espinel-Ingroff)b
CLSI 
ECVsc
EUCAST 
ECVsd
CLSI 
BPs S�/R� 
EUCAST 
BPs S�/R>e
Voriconazole 7/10 1526/1626 0.12 0.5 0.5 1 1 d 1/2 
Posaconazole 8/10 961/1035 0.12 0.25 0.25 0.25 0.25 d 0.125/0.25 
Itraconazole 7/8 989/1064 0.5 2 2 1 1 d 1/2 
Amphotericin  B 9/10 1027/1039 0.5 2 2 2 1 d 1/2 
Caspofungin 5/9 806/892 0.03 0.12* d 0.5 d d d 
Micafungin 5/8 361/372 0.008 0.016* d d d d d 
Abbreviations: BP, breakpoint; ECV, epidemiological cut-off value; MIC mode, most frequent MIC in the distribution; R, resistant; S, susceptible; SC, species complex 
*ECV obtained after data normalization (>50% of data were from one laboratory).
a ECVs calculated for the modelled population (�97.5%). 
b ECVs based on the Etest method determined by Espinel-Ingroff et al. (�97.5%) [10,11,13]. 
c ECVs determined with the CLSI method in previous studies [10,13]. 
d ECVs determined with the EUCAST method [5,9,10,23]. 
e EUCAST breakpoints [6]. 
All the previously published ECVs were calculated by only one team. Our multi-laboratory study allowed 
consolidation of these 
 previous ECV data and validation of our results. Speciﬁcally, 17/32 of our ECVs are identical to previous ones, 
and 15/32 show just one two-fold dilution [10,11,13], a difference that we consider not sig- niﬁcant (our 
deﬁnition is more stringent than the essential agree- ment, which considers two log2 dilutions). These not 
signiﬁcant differences can be explained by the higher number of laboratories and isolates included in our 
study for the ECV calculations. How- ever, ideally only one ECV should be proposed for each 
specieseantifungal combination. For that, our data and the previ- ous data should be  combined and  
analysed again to  reach  a consensus. 
Comparison of our Etest ECVs with the ECVs obtained with the reference methods indicated that they were 
identical to or within one two-fold dilution of the CLSI ECVs in 76.1% of cases [9,12,15e17,19] and to the 
EUCAST ECVs in 81.2% of cases [9,10,14,22]. Discrepancies among ECVs obtained with different methods 
were previously reported [13,24], emphasizing the importance of using ECVs speciﬁc for the in vitro method 
used to test the antifungal susceptibility. Moreover, for each specieseantifungal combination, it is possible to 
know whether the MIC distributions obtained with the Etest are close to the distri- butions obtained with the 
CLSI and EUCAST methods. For example, for C. lusitaniae and ﬂuconazole, the Etest MIC distributions were 
identical to those obtained with the CLSI but not the EUCAST method (difference of four log2 dilutions). 
This can be useful for using the available breakpoints. 
As Etest is the most widely used commercial method in French laboratories, the goal of this study was to 
calculate speciﬁc ECVs for this method. Inter-method variability and comparison of the Etest method with a 
reference method were previously performed with good essential agreement [26,29,30]. It is now important to 
have data on Etest MIC distributions for MIC interpretation in routine clinical practice and for the detection of 
non-WT isolates. When the MIC value is higher than the ECV, the search for possible gene mutations to that 
antifungal agent should be recommended. 
Conclusions 
This study identiﬁed 48 ECVs speciﬁc for the Etest method to facilitate MIC interpretation. They should 
not be used instead of breakpoints, but they may be useful to identify non-WT isolates with potential 
resistance to antifungal agents and to suggest that an isolate may not respond as expected to the standard 
treatment. ECVs have a place in the surveillance and monitoring of the emergence of drug resistance. It 
will be interesting to prospectively collect and pool MIC data to conﬁrm the calculated Etest ECVs and to 
determine other ECVs, especially for rare species. Testing isolates with acquired resistance mutations 
characterized by molecular methods will also provide a way to verify these ECVs. 
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